Macitentan
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
MACITENTAN: Repurposing Evaluation — Insufficient Evidence Pack Data
One-Sentence Summary
Macitentan is an endothelin receptor antagonist with established international approval for pulmonary arterial hypertension (PAH), but currently holds no marketing authorization in Taiwan. The present Evidence Pack does not contain TxGNN repurposing predictions, as two upstream data gaps — TFDA package insert warnings and mechanism of action data — remain unresolved. A full repurposing evaluation cannot proceed until these gaps are remediated and the TxGNN pipeline is re-executed.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not retrievable from Taiwan licenses (0 authorizations on file); international: Pulmonary Arterial Hypertension (PAH) |
| Predicted New Indication | Not available — TxGNN predictions absent from Evidence Pack |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not evaluable |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack (Data Gap DG002, severity: High). Based on publicly available pharmaceutical knowledge, Macitentan is a dual endothelin receptor antagonist (ERA) that competitively and specifically inhibits the binding of endothelin-1 (ET-1) to both ETA and ETB receptors in vascular smooth muscle cells and endothelium. This blockade reduces pulmonary vascular resistance, pulmonary arterial pressure, and vascular remodeling — the core pathophysiology of PAH.
The endothelin axis plays a broader role in fibrosis, inflammation, and aberrant vascular remodeling beyond the pulmonary circulation. This mechanistic breadth is precisely why ERAs like Macitentan are considered candidates for repurposing into conditions such as systemic sclerosis-related complications, cardiac sarcoidosis, and portal hypertension — areas where ET-1 dysregulation has been documented. Whether TxGNN has identified any of these as high-confidence repurposing targets for Macitentan specifically cannot be confirmed until predictions are generated.
Since the predicted_indications array in this Evidence Pack is empty, no formal mechanistic alignment analysis or evidence strength assessment can be completed at this stage.
Clinical Trial Evidence
Currently no TxGNN-predicted indication is available. Clinical trial evidence cannot be tabulated until repurposing candidates are generated by the model.
Literature Evidence
Currently no TxGNN-predicted indication is available. Literature evidence cannot be tabulated until repurposing candidates are generated by the model.
Taiwan Market Information
Macitentan has not received TFDA marketing authorization in Taiwan. No license records exist in the Taiwan regulatory database as of the data cutoff (2026-04-20).
Safety Considerations
Please refer to the international prescribing information (Opsumit®, Actelion Pharmaceuticals / Janssen) for complete safety information. TFDA package insert data was not successfully parsed for this Evidence Pack (Data Gap DG001, severity: Blocking).
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for Macitentan (DB08932) is structurally incomplete — zero TxGNN repurposing predictions have been generated, and at least one Blocking data gap prevents entry into the standard safety pre-screening stage. No repurposing evaluation is possible in the current state.
To proceed, the following is needed:
- [Blocking — DG001] Retrieve and parse the TFDA package insert PDF from the TFDA official website to extract approved indications, warnings, and contraindications
- [High — DG002] Query the DrugBank API (DB08932) to populate the mechanism of action field required for mechanistic plausibility analysis
- [Required] Re-execute the TxGNN prediction pipeline after upstream data inputs are complete to generate
predicted_indicationscandidates - [Recommended] Cross-check EMA and FDA approval history for Macitentan to populate
original_indicationsas reference context - [Recommended] Assess TFDA registration pathway requirements given the current zero-authorization status in Taiwan, in case a top-ranked repurposing candidate is identified
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.